Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript

Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share, ACIP impact, market trends, growth perspective, seasonality, financial guidance and trends, including revenue, profitability and sufficiency of current capitalization, timing of results of clinical trial starts and data readout, and potential future uses of CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer, Donn Casale, senior vice president of commercial, Rob Janssen, senior medical officer, and Kelly MacDonald, chief financial officer.